Lido Advisors
UTHR icon

Lido Advisors’s United Therapeutics UTHR Stock Holding History

Lido Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$982K Buy
1,812
+159
+10% +$89.5K ﹤0.01% 1100
2026
Q1 		$981K Buy
1,653
+1,009
+157% +$503K ﹤0.01% 975
2025
Q4 		$275K Buy
644
+69
+12% +$32.1K ﹤0.01% 1609
2025
Q3 		$241K Buy
+575
New +$193K ﹤0.01% 1600
2021
Q4 		– Sell
-1,554
Closed -$286K – 1050
2021
Q3 		$286K Buy
+1,554
New +$306K ﹤0.01% 766
2020
Q3 		– Sell
-2,116
Closed -$256K – 692
2020
Q2 		$256K Sell
2,116
-53
-2% -$5.96K 0.01% 489
2020
Q1 		$206K Buy
+2,169
New +$206K 0.01% 515

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Lido Advisors's UTHR Position: Q2 2026 in Review

Lido Advisors increased its United Therapeutics (UTHR) stake by 9.6% in Q2 2026, buying an estimated $89.5K and bringing the position to 1,812 shares worth $982K. The position accounts for ﹤0.01% of the portfolio, ranked #1100.

Lido Advisors first reported a position in UTHR in Q1 2020 and has held it in 7 quarters since. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Lido Advisors held 1,812 shares of United Therapeutics worth $982K as of Q2 2026.
  • Lido Advisors bought 159 United Therapeutics shares in Q2 2026, an estimated $89.5K.
  • United Therapeutics made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1100 holding.
  • Lido Advisors first reported a position in United Therapeutics in Q1 2020 and has held it in 7 quarters since.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.